Home Page

The School of Medicine Basic Sciences and the Office of the Vice Provost for Research and Innovation launch the Innovation Ignition Fund. This pilot program offers up to $500,000 in funding and drug development mentorship from Vanderbilt scientists with expertise in translational research. Read More

Researchers in the lab of Vivian Weiss, assistant professor of pathology, microbiology, and immunology, recently published a review article in Cancer Research that describes the role of the Wnt pathway in TAMs and tumor biology. Read More

An international collaboration led by Vanderbilt researchers has identified a key component in lesions associated with age-related macular degeneration (AMD), a leading cause of blindness in older adults. Read More

Anti-aging researcher and National Academy of Sciences member Monica Driscoll (Rutgers University) to deliver the Vanderbilt Basic Sciences Apex Lecture. Read More

Erin Calipari works to understand how drugs like opioids and cocaine alter learning circuits and neurochemistry in one of the country's epicenters of substance use disorder and addiction. Read More

Kit Neikirk, postbaccalaureate research intern in the lab of Antentor O Hinton Jr., has been named a 2024 Marshall Scholar by the British government. As a Marshall Scholar, Neikirk will pursue a master’s in public health and an advanced degree in biomedical imaging at University of Edinburgh and University College London, respectively. Read More

Neuroscientist Saman Abbaspoor in the Hoffman lab won the NIH BRAIN Initiatve's annual Show Us Your BRAINs! Photo and Video contest. The clip shows how “sharp-wave ripples", different layers of neural activity in the hippocampus, are wirelessly recorded to help study memory. Read More

Second only to lung cancer, colorectal cancer is the nation’s leading cancer killer — accounting for more than 52,000 deaths in the United States each year. Colorectal cancers are divided into two main groups, based on microsatellites, or repeat sections, in their DNA. Read More

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark.  “Vanderbilt is proud that a discovery by our researchers at the Warren Center… Read More